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Abstract
Background: Our study’s aim was to evaluate the prognostic value of early and intensive
lipid-lowering treatment on ventricular premature beat or non-sustained ventricular tachycardia
(NSVT) after acute coronary syndrome (STEMI, non-STEMI, and unstable angina pectoris).
Methods: Some 586 patients with acute coronary syndrome were randomly divided into two
groups: Group A (with conventional statin therapy, to receive 10 mg/day atorvastatin, n = 289)
and Group B (given early and intensive statin therapy, 60 mg immediately and 40 mg/day
atorvastatin, n = 297). The frequency of ventricular premature beat and NSVT was recorded
via Holter monitoring after hospitalization (24 h and 72 h).
Results: Seventy seven (11.8%) patients had NSVT. When compared to patients with no
documented NSVT, patients with NSVT were older and more frequently had myocardial
infarction in their history, diabetes mellitus, atrial fibrillation and an ejection fraction < 40%.
Ventricular premature beats decreased significantly in the early and aggressive treatment
group (24 h, p < 0.01; 72 h, p < 0.001). A significant reduction in NSVT was seen in the
early and aggressive treatment group (24 h, p < 0.01; 72 h, p < 0.001). There were no side
effects observed in either group.
Conclusions: Early and intensive lipid-lowering treatment can clearly decrease ventricular
premature beats and NSVT. (Cardiol J 2010; 17, 4: 381–385)
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Introduction
Statins have been proven to be very effective
in reducing mortality rates after acute coronary
syndrome (ACS). This beneficial effect has prima-
rily been attributed to lowering blood cholesterol
and thereby attenuating the progression of arterio-
sclerosis [1–4]. However, recent data suggests that
the beneficial effects of statins may extend to mecha-
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nisms beyond cholesterol reduction [5–7]. These
pleiotropic effects include improvement of endo-
thelial function, inhibition of platelet function and
smooth muscle cell proliferation, enhancing stabi-
lity of arteriosclerotic plaques, and attenuating vas-
cular inflammation. Recent evidence has shown that
statins might exert antiarrhythmic effects, both in
experimental models and in humans [8–15]. The asso-
ciation of ventricular premature beat (VPB) and non-
-sustained ventricular tachycardia (NSVT) with ad-
verse outcome after ACS could be influenced by these
agents. The early and intensive relationship between
atorvastatin in patients with ACS during early hospi-
talization in terms of antiarrhythmic effects is unclear.
In this study, we analyzed the effects of early
and intensive atorvastatin on the prognostic impact
of VPB and NSVT after acute coronary syndrome.
Methods
In the present study, all data was recorded. De-
mographic data, the patient’s history, procedural
details, the outcome, and follow-up data were re-
corded using four case report forms. The first form
recorded the data necessary for diagnosis and spe-
cification of ACS (symptoms, electrocardiography,
and cardiac enzymes). The second form included the
patient’s history (concomitant disease and previous
cardiovascular events) and acute therapy (medica-
tion, coronary angiography and reperfusion thera-
py). Case report form three included elective diag-
nostic and therapeutic procedures (echocardio-
graphy, Holter monitoring and medication) and
clinical events until discharge of the patient.
Evaluation of Holter monitoring was performed
thrice by one professional physician. Diagnostic
procedures for Holter monitoring involvedat least
a 72-hour continuous registration; mean heart rate,
total number of VPBs and total number of ventric-
ular tachycardias had to be registered in the corre-
sponding case report form. NSVT was defined as
three or more consecutive VPBs with a rate of more
than 100 beats per minute. Left ventricular func-
tion was measured by angiography, or semi-quan-
titatively by echocardiography (four-chamber view).
Some 586 consecutive patients with ACS who
were admitted to our institution were randomly
assigned, in a double-blind manner, to receive ator-
vastatin treatment. Group A (with conventional sta-
tin therapy, n = 289) received 10 mg/day atorvas-
tatin within the first 24 hours after admission, while
Group B (early and intensive statin therapy, n =
= 297) received 60 mg immediately and 40 mg/day
atorvastatin thereafter. All but seven of the patients
completed the study. A further four patients in
Group A and three patients in Group B were ex-
cluded after completion because they died. Exclu-
ded patients were evenly distributed over both
treatment groups (c2, 0.58; p = 0.75). There were
no differences between the two groups for the com-
parison of baseline clinical characteristics adjusted
for age, gender, body mass index, prior myocardial
infarction, blood pressure, prior percutaneous coro-
nary intervention (PCI), coronary artery bypass graft
(CABG), history of heart failure, hypertension, dia-
betes mellitus, smoking, alcohol abuse, ejection frac-
tion < 40%, sinus rhythm at admission, atrial fibrilla-
tion, atrioventricular block, beta-blocker use, calcium-
blockers, or angiotensin-converting enzyme inhibitor
use (Table 1).
The protocol was approved by the institutional
review board at our institution and informed consent
was obtained from all study patients.
Statistical analysis
The primary aim of our study was to investi-
gate the association of VPB and NSVT with adverse
prognosis after ACS under the conditions of modern
medical treatment. The second aim was to test the
hypothesis based on recent scientific data that sta-
tins may influence this association. Absolute num-
bers, percent, mean, and standard deviation were
computed to describe the patient population. Cate-
gorical variables were compared using the c2 or
Fisher’s exact test. Evaluating the baseline cha-
racteristics, p-values were only used in a descrip-
tive way to show differences among the two groups
under investigation (Tables 1–4). In this analysis,
adjustment was performed for the following vari-
ables: age, history of myocardial infarction, systemic
hypertension, diabetes mellitus, smoking, ejection
fraction < 40%, and sinus rhythm at admission, atrial
fibrillation, and atrioventricular block. These vari-
ables were selected according to their clinical rele-
vance. P-value < 0.05 was considered to be statis-
tically significant. All statistical analyses were car-
ried out using the Statistical Package for Social
Science (SPSS, version 12.0.2, 24 March 2005).
Results
For this study, 579 patients with ACS were ran-
domly divided into two groups. Group A (with con-
ventional statin therapy, to receive 10 mg/day ator-
vastatin, n = 289) and Group B (early and inten-
sive statin therapy, 60 mg immediately, and then
40 mg/day atorvastatin, n = 297). The results show
that early and intensive statin therapy compared to
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Table 1. Comparison of baseline clinical characteristics between the two groups.
Baseline clinical characteristics Conventional Early and intensive Statistical P
statin therapy  statin therapy  value
(n = 285) (n = 294)
Age (years; mean ± SD) 58.45 ± 10.54 60.87 ± 9.89 t = 0.368 0.683
Sex (male/female) 198/87 211/83 c2 = 0.776 0.378
Systolic pressure [mm Hg] 138.82 ± 12.42 139.37 ± 11.83 t = 0.463 0.385
Diastolic pressure [mm Hg] 86.42 ± 7.31 87.42 ± 8.36 t = 0.547 0.576
Body mass index [kg/m2] 23.62 ± 3.01 24.68 ± 2.94 t = 0.337 0.585
Past medical history:
Myocardial infarction 32 34 c2 = 0.052 0.887
PCI 56 60 c2 = 0.037 0.864
CABG 9 8 c2 = 0.505 0.448
Cardiac inadequacy 19 17 c2 = 0.347 0.561
Risk factors:
Systemic hypertension 168 172 c2 = 0.387 0.548
Diabetes mellitus 98 101 c2 = 0.239 0.617
Smoking 102 99 c2 = 0.533 0.584
Alcohol abuse 16 19 c2 = 0.667 0.412
Ejection fraction < 40% 26 28 c2 = 0.237 0.624
Sinus rhythm at admission 274 278 c2 = 0.007 0.918
Atrial fibrillation 11 16 c2 = 0.234 0.641
Atrioventricular block 40 43 c2 = 0.247 0.638
Combination therapy:
Diuretic 39 41 c2 = 0.372 0.537
Beta-blockers 246 251 c2 = 0.014 0.901
Ca2+channel blockers 71 76 c2 = 0.277 0.684
ACE-inhibitors 285 294 c2 = 0.000 0.991
PCI — percutaneous coronary intervention; CABG — coronary artery bypass graft; ACE — angiotensin-converting enzyme
Table 2. Comparison of the numbers of ventricular premature beats (VPB) between the two groups.
Group N VPB in 24 h VPB in 24–72 h Total VPB in 72 h
(episode)  (episode)  (episode)
Conventional statin therapy 285 1243±104 1568±121 2658±127
Early and intensive statin therapy 294 532± 83 562± 87 1073±91
P 0.006 0.003 < 0.001
Table 3. Baseline characteristics of patients after acute coronary syndrome either presenting with
non-sustained ventricular tachycardia (NSVT) during Holter monitoring or not.
Baseline clinical characteristics No NSVT (n = 502) NSVT (n = 77) P
Age (years; mean ± SD) 58.37 ± 10.84 66.8 ± 9.34 < 0.001
History of myocardial infarction 7.5% (38/502) 36.3% (28/77) < 0.001
History of systemic hypertension 58.1% (292/502) 62.3% (48/77) 0.624
History of diabetes mellitus 31.4% (158/502) 53.2% (41/77) 0.008
Smoking 34.6% (174/502) 35.1% (27/77) 0.423
Ejection fraction < 40% 6.7% (34/502) 25.9% (20/77) < 0.001
Sinus rhythm at admission 96.4% (484/502) 88.3% (68/77) 0.864
Atrial fibrillation 3.5% (18/502) 11.7% (9/77) 0.007
Atrioventricular block 14.1% (71/502) 15.6% (12/77) 0.495
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conventional statin therapy can significantly reduce
VPB whether over 24 hours or between 24–72
hours (p = 0.006; p = 0.003). The statistic for total
VPBs in 72 hours was p < 0.001, suggesting statisti-
cal significance. The mean heart rate in the two groups
was: Group A 81.3 ± 6.7; Group B 79.6 ± 6.4;
p = 0.783, suggesting no statistical significance.
Table 3 shows the baseline characteristics of
patients with and without NSVT during Holter
monitoring either under early and intensive statin
therapy or conventional statin therapy. In general,
patients with NSVT were older (66.8 ± 9.34 vs
58.37 ± 10.84 years, p < 0.001), more often had
myocardial infarction in their history (36.3 vs 7.5%,
p < 0.001), had an ejection fraction < 40% (25.9 vs
6.7%, p < 0.001), and had atrial fibrillation more
often (11.7 vs 3.5%, p = 0.007) at admission.
Table 4 shows that early and intensive statin
therapy compared to conventional statin therapy can
significantly reduce the cases with NSVT (p = 0.008)
whether over 24 hours or in 24–72 hours (p = 0.007).
The statistic for total NSVT in 72 hours was p < 0.001,
suggesting statistical significance. Almost all pa-
tients showed good tolerance of 20 mg/day ator-
vastatin. All these results of our study indicate that
early and intensive statin therapy with (60 mg im-
mediately, 40 mg/day) atorvastatin is more effica-
cious than (and as safe as) 10 mg/day atorvastatin
when administered to patients during early hospi-
talization for ACS.
Discussion
It is well-known that a significant proportion
of the patients who die after ACS, die suddenly be-
cause of severe arrhythmias [13]. In some early
experimental animal models, researchers have
demonstrated that statins can significantly decrease
reperfusion injury and limit myocardial infarction
size [5, 6]. Many studies show that patients with
ACS treated with statins early (i.e. within 24 h of
hospitalization) would have lower in-hospital mor-
bidity and mortality risks than patients not treated
with statins [2–4], but the effectiveness regarding
antiarrhythmias in the patients with ACS receiving
immediate and intensive statin therapy were not
clear. The present study shows the occurrence of
VPBs and NSVT after ACS being associated with
an increased mortality. However, this adverse ef-
fect only applies to patients not on statin therapy.
Atorvastatin significantly reduces mortality,
irrespective of the absence or presence of VPBs and
NSVT. The present study shows that atorvastatin
are able to markedly attenuate the association of VPBs
and NSVT with adverse outcomes after ACS [16]. Pa-
tients with or without VPBs and NSVT did not
largely differ in medication including angiotensin-
-converting enzyme-inhibitors, beta-blockers etc.
As expected, however, patients with VPBs and
NSVT were older and more often had previous myo-
cardial infarction, severely reduced left ventricular
function and atrial fibrillation. Taking these parame-
ters into account, only VPB and NSVT were asso-
ciated with a trend to adverse prognosis. Indeed, the
independent prognostic value of VPB and NSVT in
the era of modern treatment of myocardial infarction
including thrombolysis, PCI, beta-blockers, and st-
atins is controversial and has been questioned pre-
viously. The situation completely changes if the
prognostic value of VPB and NSVT is evaluated with-
in the patients receiving immediate and intensive
statin therapy [17–19]. In the present study, early
and intensive atorvastatin therapy can significantly
decrease the recurrence of VPB and NSVT. It may
therefore be suggested that one of the beneficial
mechanisms of statins could be to rapidly affect sig-
nalling pathways in cell membranes of the myocar-
dium and/or the autonomic nervous system, there-
by protecting patients from life-threatening arrhyth-
mias [20–22]. This assumption would be in line with
recent data showing statins to improve autonomic
neural control and increase electrical stability of the
myocardium. Atorvastatin is a highly lipophilic drug
that becomes easily embedded into the membrane
having overlapping locations in the hydrocarbon core
adjacent to the phospholipid headgroups [23–26].
Moreover, the blocking effects could be attributed
to an effect on the lipid content of the membrane [27].
Table 4. Comparison of the numbers of patients with non-sustained ventricular tachycardia (NSVT) and
the number with NSVT between the two groups.
Group NSVT in 24 h Total NSVT in Total NSVT in Total NSVT in
(patients)  24 h (episode)  24–72 h (episode) 72 h (episode)
Conventional statin therapy 23.2 (56/285) 363 ± 32 132 ± 36 583 ± 31
Early and intensive statin therapy 7.1 (21/294) 186 ± 27 78 ± 31 207 ± 29
p 0.008 0.007 0.007 < 0.001
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Conclusions
The present study supports the experimental
data, as the benefit is probably due to  immediately
improving autonomic neural control and increasing
electrical stability of the ischemic myocardium, as
well as having an antiarrhythmia effect.
Since you’re going to use the drug anyway, you
might as well start it right away, given that there
might be an added benefit that occurs quite early.
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